ATTAIN-1
The pivotal Phase 3 trials and post-approval cardiovascular, kidney, and sleep-apnea outcome studies.
Definition
Phase 3 randomized trial of orforglipron (Foundayo) for chronic weight management in adults with obesity without diabetes. 72 weeks, N=3,127, conducted across 10 countries (NCT05869903). Primary outcome: −12.4% body weight on 17.2 mg orforglipron vs −0.9% placebo (efficacy estimand); −11.1% vs −2.1% (treatment-regimen estimand). Drove the April 2026 FDA approval of Foundayo — the first FDA-approved oral non-peptide GLP-1 receptor agonist for weight management.
Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.
Related terms in Major trials
Looking for more depth?
- Foundayo drug overview
- Browse the full GLP-1 glossary (71 terms across 8 categories)
- Research articles — primary-source deep dives
- Tools and calculators
- Compare GLP-1 telehealth providers